The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 26, 2023
Filed:
Dec. 07, 2016
Fundació Privada Institut D'investigació Oncológica DE Vall D'hebron, Barcelona, ES;
Fundación Solti, Barcelona, ES;
Fundación Para El Fomento DE LA Investigación Sanitaria Y Biomédica DE LA Comunitat Valenciana, Valencia, ES;
Hospital Clínic DE Barcelona, Barcelona, ES;
Aleix Prat Aparicio, Barcelona, ES;
Javier Cortés Castán, Barcelona, ES;
Antonio Llombart Cussac, Valencia, ES;
FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL D'HEBRON, Barcelona, ES;
FUNDACIÓN SOLTI, Barcelona, ES;
FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA, Barcelona, ES;
HOSPITAL CLÍNIC DE BARCELONA, Barcelona, ES;
Abstract
The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.